What can breast and lung cancer oncologists learn from each other about TROP2-directed antibody-drug conjugates?

Dr. Komal Jhaveri, Dr. Paolo Tarantino, and Dr. Jacob Sands discuss the role of datopotamab deruxtecan (Dato-DXd) across breast and lung cancer, examining clinical trial findings, patient selection, and practical approaches to treatment.

Drawing on the TROPION-Breast and TROPION-Lung trials, they address differences in efficacy across patient populations, emerging biomarkers, toxicity management, and the challenges of ADC sequencing and resistance.

Topics discussed:

• Dato-DXd efficacy in breast and lung cancer

• TROPION-Breast01, TROPION-Breast02, TROPION-Lung01, and TROPION-Lung05 findings

• EGFR mutations and TROP2 biomarkers

• Brain metastases and intracranial activity

• Dato-DXd and sacituzumab govitecan

• Stomatitis, ocular toxicity, and ILD management

• ADC sequencing and cross-resistance

• Next-generation ADC strategies

Watch the full CHM Conversation for expert perspectives on translating Dato-DXd evidence across breast and lung cancer into clinical practice.

▶️ https://youtu.be/e2aWLCMD_mk

#KomalJhaveri #PaoloTarantino #JacobSands #CHMConversations #DatoDXd #TROP2 #AntibodyDrugConjugates #BreastCancer #LungCancer #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

When an ESR1 mutation emerges before radiographic progression, what comes next?

Dr. Jason Mouabbi, Dr. Joyce O'Shaughnessy, and Dr. Erica Mayer discuss findings from the SERENA-6 trial, focusing on the use of circulating tumor DNA (ctDNA) to identify emerging ESR1 mutations during first-line endocrine therapy.

They examine the progression-free survival benefit observed when patients with newly detected ESR1 mutations switched from an aromatase inhibitor to camizestrant while continuing their existing CDK4/6 inhibitor. The conversation also addresses ctDNA response findings, patient-reported quality-of-life outcomes, and the practical considerations of implementing molecular surveillance before radiographic progression.

Topics discussed:

• ESR1 mutations as a mechanism of endocrine resistance

• SERENA-6 trial design and progression-free survival findings

• ctDNA clearance and changes in ESR1 variant allele frequency

• Patient-reported quality-of-life outcomes and time to chemotherapy

• Camizestrant safety considerations, including photopsia, bradycardia, and QTc monitoring

• Timing and implementation of ESR1 mutation testing

• Continuing CDK4/6 inhibition after an endocrine therapy switch

• Unanswered questions about oral SERD sequencing and future treatment strategies

Watch the full CHM Conversation to hear how these experts interpret the SERENA-6 findings and discuss their potential application in clinical practice.

▶️ https://youtu.be/bcvuFLVWBmE

#JasonMouabbi #JoyceOShaughnessy #EricaMayer #CHMConversations #SERENA6 #Camizestrant #ESR1 #ctDNA #OralSERDs #MetastaticBreastCancer #EndocrineResistance #CDK46Inhibitors #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How are TROP2-directed antibody-drug conjugates (ADCs) changing treatment decisions in breast and lung cancer?

Dr. Jason Mouabbi is joined by Dr. Rebecca Shatsky and Dr. Ryan Gentzler to discuss the clinical evidence behind datopotamab deruxtecan (Dato-DXd), its role across breast and lung cancer, and the challenges of selecting and sequencing ADC therapies.

Drawing on findings from TROPION-Breast02, ASCENT-03, TROPION-Lung01 and TROPION-Lung05, they examine efficacy, emerging data in brain metastases, treatment-related toxicities, and the potential of ADC combinations with immunotherapy and targeted agents.

Topics discussed:

• Dato-DXd and sacituzumab govitecan in metastatic TNBC

• TROP2 ADCs in EGFR-mutated lung cancer

• Brain metastases and intracranial activity

• ADC sequencing and treatment selection

• Managing stomatitis, ocular toxicity, and ILD

• Emerging ADC combinations and future directions

Watch the full CHM Conversation for expert perspectives on translating ADC evidence into treatment decisions across breast and lung oncology.

▶️ https://youtu.be/99AchJ1ZlnU

#JasonMouabbi #RebeccaShatsky #RyanGentzler #CHMConversations #BreastCancer #LungCancer #AntibodyDrugConjugates #DatoDXd #TROP2 #TNBC #NSCLC #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

When an ESR1 mutation emerges as a sign of endocrine resistance before radiographic progression, what do we do next?

Dr. Neil Iyengar, Dr. Sarah Sammons, and Dr. Tiffany Traina discuss the SERENA-6 trial and what it means for identifying endocrine resistance earlier through circulating tumor DNA (ctDNA) monitoring in HR-positive, HER2-negative metastatic breast cancer.

They examine the clinical evidence behind switching from an aromatase inhibitor to camizestrant at ESR1 detection while continuing CDK4/6 inhibition, including progression-free survival, ctDNA clearance, and patient-reported outcomes. The conversation also addresses practical challenges around molecular surveillance, treatment safety, patient selection, and the open questions around long-term outcomes and subsequent treatment sequencing.

Topics discussed:

• Risk stratification and endocrine resistance in HR+/HER2− metastatic breast cancer

• ESR1 mutations and ctDNA surveillance

• SERENA-6 trial design, efficacy, and clinical implications

• Camizestrant safety, including photopsia, bradycardia, and QTc/EKG monitoring

• Patient preferences and implementing molecular surveillance

• Switching at ESR1 detection or waiting for radiographic progression

• Implications for subsequent endocrine and targeted therapies

Watch the full CHM Conversation for expert perspectives on integrating SERENA-6 findings into clinical practice and individualizing treatment for HR-positive metastatic breast cancer.

▶️ https://youtu.be/_RSMxK86O60

#NeilIyengar #SarahSammons #TiffanyTraina #CHMConversations #SERENA6 #ESR1 #Camizestrant #BreastCancer #MetastaticBreastCancer #ctDNA #CDK46Inhibitors #EndocrineResistance #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Could CLDN18.2-targeted antibody-drug conjugates (ADCs) expand treatment options for patients with advanced gastric cancer?

Recorded at ESMO 2026 in Madrid, Dr. Yelena Janjigian moderates a roundtable with Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Arturo Loaiza-Bonilla, Dr. Sunnie Kim, and Dr. David Zhen on emerging CLDN18.2-targeted therapies in gastric and gastroesophageal junction adenocarcinoma.

The panel examines the phase III CLARITY-Gastric01 results for the ADC Sone-Ve and their potential implications for biomarker testing, treatment selection, and sequencing.

Topics discussed:

• CLDN18.2 testing and expression thresholds

• Zolbetuximab and first-line treatment decisions

• Sone-Ve's mechanism of action and MMAE payload

• CLARITY-Gastric01 survival and efficacy results

• Outcomes across CLDN18.2 expression levels

• Second-line and later-line treatment sequencing

• Safety, tolerability, and adverse event management

• Future directions for CLDN18.2-targeted ADCs

What could these findings mean for clinical practice and the future of gastric cancer treatment?

▶️ Watch the full CHM Conversation and subscribe for more expert discussions - https://youtu.be/3KPT2ScVsx4

#CHMConversations #ESMO2026 #GastricCancer #CLDN182 #SoneVe #CLARITYGastric01 #AntibodyDrugConjugates #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Should an emerging ESR1 mutation prompt a treatment change before radiographic progression?

Dr. Rebecca Shatsky, Dr. Melinda Telli, and Dr. Anastasia Martynova discuss the SERENA-6 trial and how its findings are influencing clinical practice in HR-positive, HER2-negative metastatic breast cancer. They examine the evidence for switching endocrine therapy upon molecular progression with ESR1 mutation emergence, while maintaining CDK4/6 inhibition, along with the practical challenges of bringing this strategy into routine care.

Topics discussed:

• SERENA-6 trial design, progression-free survival results, and the debate over treatment-line definitions

• ESR1 mutations as a mechanism of endocrine resistance and the rationale for switching before radiographic progression

• ctDNA monitoring frequency, testing burden, and patient anxiety

• Selecting patients for ESR1 monitoring, including considerations in invasive lobular breast cancer

• Patient-reported outcomes, quality of life, and time to subsequent chemotherapy

• Camizestrant safety, including bradycardia, photopsia, QTc prolongation, and EKG monitoring

• Real-world implementation of SERENA-6, including treatment sequencing and the role of oral SERDs

How are clinicians deciding when to test, whom to monitor, and when to change treatment?

▶️ Watch the full CHM Conversation - https://youtu.be/lfILkeclvDk

#CHMConversations #SERENA6 #Camizestrant #ESR1 #BreastCancer #ctDNA #MetastaticBreastCancer #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast...

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Trastuzumab deruxtecan (T-DXd) now spans the HER2-positive breast cancer continuum, from first-line metastatic to early-stage disease.

Recorded at ESMO 2026, Dr. Jason Mouabbi moderates a CHM roundtable with Dr. Sara Hurvitz, Dr. Neil Iyengar, Dr. Heather McArthur, Dr. Erika Hamilton, Dr. Paolo Tarantino, and Dr. Tiffany Traina on the clinical implications of DESTINY-Breast09, DESTINY-Breast11, and DESTINY-Breast05.

The panel examines the efficacy of T-DXd, treatment duration, maintenance strategies, toxicity management, and the challenges of applying emerging evidence to patients with HER2-positive breast cancer.

Topics discussed:

• DESTINY-Breast09: T-DXd plus pertuzumab versus THP

• Progression-free survival and subgroup outcomes

• Complete and deep partial responses

• Induction duration and maintenance strategies

• PATINA and HER2CLIMB-05 treatment sequencing

• Brain metastases and treatment selection

• Managing fatigue, nausea, and ILD

• DESTINY-Breast11 and neoadjuvant treatment

• MRI, ctDNA, and response assessment

• DESTINY-Breast05 and adjuvant T-DXd versus T-DM1

• Residual disease and individualized treatment decisions

The panel shares how they balance efficacy, long-term tolerability, and a growing number of treatment options in HER2-positive breast cancer.

Watch the full CHM Conversation for an in-depth discussion of the latest findings and their implications for HER2-positive breast cancer treatment.

▶️ https://youtu.be/G9oP7BgdVrI

#CHMConversations #ESMO2026 #DESTINYBreast09 #DESTINYBreast11 #DESTINYBreast05 #HER2PositiveBreastCancer #BreastCancer #TrastuzumabDeruxtecan #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Can AI help distinguish who truly benefits from chemo in early hormone receptor–positive breast cancer?

Dr. Jason Mouabbi and Dr. VK Gadi discuss artificial intelligence (AI) in early hormone receptor–positive, HER2-negative breast cancer, focusing on prognostic risk and predicting treatment benefit.

Drawing on the TAILORx trial and genomic assays like Oncotype DX, they cover Ataraxis Breast, an AI digital pathology test that reads H&E slides to estimate recurrence risk and who may benefit from chemo. They also discuss anticipated analyses of Ataraxis on TAILORx data, including in the intermediate-risk group.

Topics discussed:

• Prognostic and predictive testing in early-stage breast cancer

• TAILORx findings and existing genomic assays

• AI-based digital pathology and H&E slide analysis

• Ataraxis in recurrence risk assessment and chemotherapy benefit prediction

• Anticipated TAILORx-based analyses at the San Antonio Breast Cancer Symposium

• Risk assessment in premenopausal patients and invasive lobular carcinoma

• Integrating AI-based testing into clinical workflows

• Unanswered questions about chemotherapy benefit, ovarian suppression, and future treatment prediction

Watch the full CHM Conversation to hear Dr. Mouabbi and Dr. Gadi discuss the potential applications and future research directions of AI-based pathology in breast cancer care.

▶️ https://youtu.be/4xU9jRs8Kds

#JasonMouabbi #VKGadi #CHMConversations #Ataraxis #TAILORx #ArtificialIntelligence #DigitalPathology #BreastCancer #EarlyStageBreastCancer #OncotypeDX #ChemotherapyBenefit #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media